Is There a Path Forward for mGlu2 Positive Allosteric Modulators for the Treatment of Schizophrenia?
详细信息 查看全文
- 作者：Corey R. Hopkins
- 刊名：ACS Chemical Neuroscience
- 出版年：2013
- 出版时间：February 20, 2013
- 年：2013
- 卷：4
- 期：2
- 页码：211-213
- 全文大小：144K
- 年卷期：v.4,no.2(February 20, 2013)
- ISSN：1948-7193
文摘
Two recent Phase II results show opposing outcomes for the potential of activators of mGlu2 in the treatment of schizophrenia. The first outcome revealed that Eli Lilly鈥檚 mGlu2/3 agonist, pomaglumetad methionil (LY2140023), failed to meet the primary efficacy end point. The second report showed the mGlu2 positive allosteric modulator (PAM) from Addex (ADX71149) in conjunction with Janssen Research & Development met the primary objectives of safety, tolerability and demonstrated an effect on negative symptoms in patients.